First, confirm which Vlad Coric you mean
When you search "Vlad Coric net worth," there is really one dominant public figure the data points to: Dr. Vlad Coric (also listed as Vladimir Coric, MD in academic and some SEC contexts), the Chairman and CEO of Biohaven Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company. He is the person behind the verifiable financial trail: SEC Form 4 filings, proxy disclosures, executive compensation reports, and media interviews on CNBC. His Yale School of Medicine faculty profile uses the fuller "Vladimir Coric" spelling, but it is the same individual. Outside of this figure, there is no other Vlad Coric with a significant documented public financial footprint at the time of writing (April 2026). If you were searching for a different person sharing this name, the honest answer is that there is no comparable wealth data available for any other Vlad Coric in public records. Everything in this article refers to the Biohaven CEO.
What "net worth" actually means here (and why it is always an estimate)
Net worth, at its most straightforward, is total assets minus total liabilities. For a public company executive like Vlad Coric, the assets that are actually visible to the public are his disclosed equity holdings: shares, restricted stock units (RSUs), and trust-held stock that show up in SEC filings. What is invisible includes private investments, real estate, cash accounts, family trusts beyond what is required to be disclosed, and any debts or liabilities. This means every net worth figure you see for a person like Coric, whether from this site or from aggregators like Benzinga or GuruFocus, is an estimate constructed primarily from his documented stock holdings and known compensation, not from a full personal balance sheet. The number will also shift constantly as Biohaven's share price moves. On a day when BHVN stock rises 10%, his estimated net worth rises proportionally. On a bad week for biotech, it contracts. Treat any figure as a snapshot, not a fixed fact.
The net worth estimate: range, currency, and confidence level
Based on publicly disclosed holdings and compensation data available through April 2026, a defensible estimated net worth range for Vlad Coric is approximately $95 million to $130 million USD. GuruFocus, which derives its estimates directly from SEC insider ownership data, puts the floor at roughly $95 million. Benzinga, which layers in broader compensation context, estimates around $123 million. These two anchor points, both drawing from public filings rather than speculation, give a reasonable band. The midpoint around $110 million USD is a practical working estimate.
Confidence level: moderate-to-high for the disclosed equity component, low-to-moderate for the total figure. The equity piece is well-documented through SEC filings. The uncertainty comes from everything that is not publicly required to be disclosed: private holdings, compensation components paid in cash and not tracked publicly, and assets held outside his SEC-reportable positions. This is not unusual for executives of U.S.-listed companies, and it is why a range rather than a single number is always the more honest presentation.
How the estimate is built: sources and methodology
The estimate is assembled from several layers of public information, working from the most reliable down to the more inferential.
- SEC Form 4 filings: These are the backbone. Form 4 filings are mandatory disclosures whenever a company insider buys, sells, or receives shares. Coric's filings show holdings via "The Vlad Coric Family Trust" (1,195,275 common shares per the 2026 proxy) and "The Vladimir Coric Marital Trust" (740,546 common shares), plus RSU vestings and tax withholding events. The November 2025 open-market purchase of 666,666 shares at $7.50 each (approximately $5 million total) is directly reflected in these filings.
- DEF 14A proxy statement: Biohaven's 2026 definitive proxy, filed with the SEC, lists beneficial ownership by insiders including Coric's trust-held shares and references to 401(k) holdings. Proxy statements are among the most reliable wealth indicators available for U.S. public company executives.
- Executive compensation disclosures: Simply Wall St aggregates Biohaven's public filings to show Coric's total yearly compensation at approximately $13.50 million, with a breakdown between base salary and equity/bonus components. This figure originates from Biohaven's own SEC-filed compensation tables.
- Aggregator estimates: GuruFocus ($95M+) and Benzinga ($123M) both derive their figures from the above SEC data, applying their own methodologies for stock valuation timing and compensation capitalization. These are secondary sources, useful as cross-checks rather than primary evidence.
- Biographical context: Biohaven's own bio materials note Coric led the company from a pre-money valuation of roughly $6 million through to the Pfizer acquisition (originally announced at approximately $11.6 billion in cash per Pfizer's press release, with total consideration referenced at approximately $13 billion including the spinoff of the new Biohaven entity). This historical context explains how significant equity value was created during his tenure.
One important methodological note: the Pfizer acquisition closed in 2022, and the current Biohaven (NYSE: BHVN) is a separate, re-launched entity. Coric's current holdings and compensation relate to this post-spinoff company, not the original Biohaven that Pfizer purchased. Any wealth accumulated from the original acquisition would be separate from what shows up in current filings, though the total enrichment from that event likely forms a significant portion of his underlying asset base.
Income and wealth sources to verify for Vlad Coric
To build the most accurate picture possible, these are the specific wealth drivers that are either confirmed or strongly indicated by public records:
- Biohaven CEO salary and annual bonus: Reported total compensation of approximately $13.50 million per year, as aggregated by Simply Wall St from Biohaven's SEC filings. This is an ongoing income stream as long as he remains CEO.
- Biohaven equity (shares and RSUs): The 2026 proxy discloses over 1.93 million shares held across his family and marital trusts. At Biohaven's share price as of the most recent filings, this represents tens of millions of dollars in equity. RSU vesting events (such as the January 2026 vest of 14,250 RSUs, with 7,430 shares withheld for taxes) add incrementally to his holdings over time.
- Open-market share purchases: The November 2025 purchase of approximately $5 million in BHVN shares at $7.50 per share is a matter of public record and signals both his financial capacity and conviction in the company's prospects.
- Proceeds from the original Biohaven/Pfizer deal (2022): As CEO and a significant equity holder of the original Biohaven Pharmaceuticals, Coric would have received merger consideration when Pfizer completed its acquisition. The exact amount he personally received is not publicly itemized, but given his leadership role and multi-year equity accumulation, this is likely a substantial component of his total wealth.
- Veradermics board directorship: Coric sits on the board of Veradermics (MANE), a separate company, with Form 4 filings filed under "Vladimir Coric" as director. Board director compensation is typically smaller than CEO-level pay but adds to the overall picture.
- Yale academic/medical background: His faculty listing at Yale School of Medicine (as Vladimir Coric, MD) reflects a clinical and academic background, though academic roles of this type are generally not a primary wealth driver at this career stage.
- Trust structures: Holdings via the Vlad Coric Family Trust and Vladimir Coric Marital Trust suggest estate and wealth planning structures that may hold additional assets beyond what shows up as direct stock ownership.
Why the numbers differ depending on where you look
If you check three different sites, you will likely get three different numbers for Vlad Coric's net worth. Here is why that happens and how to make sense of it.
| Reason for difference | What it means in practice | How to handle it |
|---|
| Stock price timing | GuruFocus and Benzinga calculate share value at different dates; a 20% swing in BHVN stock changes the estimate by tens of millions | Check the 'as of' date on any estimate and compare it to Biohaven's share price history |
| Different share counts used | Some aggregators count only directly held shares; others include trust-held shares, RSUs, or options | The proxy statement (DEF 14A) is the most complete ownership disclosure; use it as the reference |
| Inclusion or exclusion of non-equity wealth | Some estimates attempt to include cash compensation, past liquidity events, or inferred private assets; others stick only to current equity | Understand which components a site includes before comparing its figure to another |
| Pfizer deal proceeds not tracked post-2022 | No public source itemizes what Coric personally received from the Pfizer acquisition; estimates that include this are partially inferred | Flag this as a known gap; the actual number could be meaningfully higher than equity-only estimates suggest |
| Rounding and methodology variation | Aggregator sites apply proprietary formulas that are not always disclosed | Treat aggregator figures as reference points, not authoritative answers; anchor to SEC filings |
The practical takeaway: when you see a number like $123 million from Benzinga and $95 million from GuruFocus, neither is wrong in a simple sense. They are measuring slightly different things at slightly different moments. The spread between them ($28 million in this case) reflects the genuine uncertainty in any public estimate, not sloppy research.
How to check and validate this fast: where to look next
If you want to do your own verification rather than rely on any single source, here is the shortest path to the most reliable data:
- SEC EDGAR (edgar.sec.gov): Search for "Vlad Coric" or "Vladimir Coric" under the insider filings section. Pull the most recent Form 4 filings for Biohaven (BHVN) and Veradermics (MANE). These give you exact share counts and transaction prices directly from mandatory legal disclosures.
- Biohaven's DEF 14A proxy: The 2026 proxy statement, available on SEC EDGAR or Biohaven's investor relations page, contains the beneficial ownership table. This is the single most complete picture of his equity stake.
- Biohaven investor relations page: For current share price, you can multiply Coric's disclosed share count by today's price yourself. This is more accurate than any aggregator figure because it uses real-time data.
- GuruFocus insider page for Vlad Coric: Useful as a quick cross-check on aggregate equity value with a clear methodology note about what is included.
- Benzinga's net worth page: Worth a look as a secondary estimate, but note that it includes some inferred components beyond pure SEC data.
- Biohaven corporate bio and Royalty Pharma profile: For biographical and role confirmation rather than financial figures, these confirm you are looking at the right person.
A note on the Balkan and Eastern European context: Vlad Coric operates primarily within the U.S. pharmaceutical and biotech sector, so the wealth transparency tools available are the U.S. SEC disclosure system, which is more robust than what typically exists for executives in Balkan markets. If you have been researching other figures in this region, such as Vladimir Stimac, Vladimir Radmanovic, Vladimir Stojkovic, or Vladimir Djukanovic, you will notice that the quality and depth of publicly available financial data can vary significantly depending on whether the person's primary career has been in a U. If you are looking up Vladimir Radmanovic net worth, compare what is publicly disclosed against what aggregators are estimating. If you are specifically trying to find Vladimir Stimac net worth, you will need to compare what is disclosed publicly versus what comes from estimates. S.-listed company (like Coric) or in regional markets with different disclosure standards. For Coric specifically, the SEC filing trail is genuinely strong and gives you more to work with than is typical for many Balkan-linked public figures. If you are specifically researching Vladimír Đukanović net worth, the same approach of checking primary disclosures first and then comparing aggregator estimates will help you assess credibility Vladimir Đukanović net worth.
Bottom line: The most defensible estimate for Vlad Coric's net worth as of April 2026 sits in the $95 million to $130 million USD range, grounded primarily in his disclosed Biohaven equity holdings, documented compensation of approximately $13.5 million annually, and his historical role in the Pfizer acquisition of the original Biohaven. The equity portion is well-evidenced; the full personal balance sheet remains partially opaque, as it does for virtually every private individual. Use the SEC filings as your primary anchor, treat aggregator figures as useful cross-checks, and always note the date of any estimate you rely on.
